08Jan/13

Veloxis' Phase 3 Trial of LCP-Tacro in Stable Kidney Transplant Patients, the … – FierceDrugDelivery

Veloxis’ Phase 3 Trial of LCP-Tacro in Stable Kidney Transplant Patients, the
FierceDrugDelivery
Non-inferiority was determined by a composite endpoint, measured over a year of follow up that included death, graft failure, biopsy-proven acute rejection or loss to follow-up. Results of this trial demonstrated that patients can be successfully

08Jan/13

Mass. Eye and Ear ophthalmologist receives Senior Scientific Investigator Award – Phys.Org (press release)

Mass. Eye and Ear ophthalmologist receives Senior Scientific Investigator Award
Phys.Org (press release)
“I am delighted to have received this support from RPB, which will aid us tremendously in our investigations of ocular surface inflammation in eyes deemed at high risk of corneal transplant rejection,” said Dr. Dana. “With this support, we will be able

08Jan/13

IncellDx Presents First Study Using Their Novel OncoBreast 3Dx‚Ñ¢ Breast … – PharmiWeb.com (press release)

IncellDx Presents First Study Using Their Novel OncoBreast 3Dx‚Ñ¢ Breast
PharmiWeb.com (press release)
About IncellDx, Inc. IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant rejection. For more

and more »

08Jan/13

IncellDx Presents First Study Using Their Novel OncoBreast 3Dx™ Breast … – The Herald | HeraldOnline.com

IncellDx Presents First Study Using Their Novel OncoBreast 3Dx™ Breast
The Herald | HeraldOnline.com
3Dx platform,” he added. About IncellDx, Inc. IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant

and more »

04Jan/13

The Cure For Cancer And HIV May Be On The Way – The Inquisitr


The Inquisitr
The Cure For Cancer And HIV May Be On The Way
The Inquisitr
The best part is the technique only boosts the power of the immune system, so the chances of transplant rejection are small. Two experiments were conducted – one targeting skin cancer and the other targeting HIV, says the BBC. The team used T-cells
Have Japanese Researchers Invented the Cure for Cancer and HIV?Medical Daily

all 71 news articles »

04Jan/13

Mass. Eye and Ear/Harvard Medical School Ophthalmologist Receives … – Newswise (press release)

Mass. Eye and Ear/Harvard Medical School Ophthalmologist Receives
Newswise (press release)
“I am delighted to have received this support from RPB, which will aid us tremendously in our investigations of ocular surface inflammation in eyes deemed at high risk of corneal transplant rejection,” said Dr. Dana. “With this support, we will be able

and more »